Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Changes Name Prepares for Public Offering



RINCETON, NJ--Orchid Biocomputer said it has changed its name to Orchid BioSciences to reflect the company’s current and future direction in the genetic diversity and pharmacogenetics fields. "Orchid has grown in new directions that didn’t exist when the company formed in 1995," said Dale Pfost, Orchid’s chairman, president, and CEO. "We believe our new name is commensurate with the future of Orchid and the many exciting possibilities that await the company, the genetics industry, and the future of medicine and bioscience."

According to a report in Nature Biotechnology, Pfost said the company is planning an initial public offering in coming weeks to capitalize on the favorable biotech markets.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.